| dc.contributor.author | Vundli, Ramakolo | |
| dc.contributor.author | Kuhn, Louise | |
| dc.contributor.author | Lombard, Carl | |
| dc.date.accessioned | 2023-03-28T07:02:30Z | |
| dc.date.available | 2023-03-28T07:02:30Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Vundli, R. et al. (2022). Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV-exposed uninfected: the national South African Prevention of Mother to Child Evaluation cohort study. BMC Infectious Diseases, 22(1), pp.1-14. https://doi.org/10.1186/s12879-022-07847-9 | en_US |
| dc.identifier.uri | https://doi.org/10.1186/s12879-022-07847-9 | |
| dc.identifier.uri | 1471-2334 | |
| dc.identifier.uri | http://hdl.handle.net/10566/8668 | |
| dc.description.abstract | Background: The relationship between in-utero antiretroviral (ARV) drug exposure and child growth needs further study as current data provide mixed messages. We compared postnatal growth in the first 18-months of life between children who are HIV-exposed uninfected (CHEU) with fetal exposure to ARV drugs (prophylaxis or triple-drug therapy (ART)) and CHEU not exposed to ARVs. We also examined other independent predictors of postnatal growth. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BMC | en_US |
| dc.subject | HIV | en_US |
| dc.subject | South Africa | en_US |
| dc.subject | Child growth | en_US |
| dc.subject | Public health | en_US |
| dc.subject | Antenatal antiretroviral drug | en_US |
| dc.title | Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV-exposed uninfected: The national South African prevention of mother to child evaluation cohort study | en_US |
| dc.type | Article | en_US |
